Compare DLTH & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTH | CNTN |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7M | 153.8M |
| IPO Year | 2015 | 2021 |
| Metric | DLTH | CNTN |
|---|---|---|
| Price | $3.89 | $1.23 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 43.4K | ★ 573.7K |
| Earning Date | 12-15-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 64.12 | ★ 88.10 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $565,184,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $1.38 |
| 52 Week High | $5.09 | $5.27 |
| Indicator | DLTH | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 28.83 |
| Support Level | $3.75 | N/A |
| Resistance Level | $4.17 | $2.30 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 13.04 | 0.50 |
Duluth Holdings Inc is an apparel brand in the United States. The company offers shirts, pants, and casual wear for men and women under brands like Alaskan Hardgear, Armachillo, Ballroom, Cab Commander, Crouch Gusset, Dry on the Fly, Duluth Trading Co, Duluthflex, Fire Hose, Longtail T, No Polo Shirt, No Yank, Wild Boar, and others. The Company's revenue consists of the sale of apparel, footwear, and hard goods. The company operates in a single operating segment.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.